Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2011 Apr 19;104(11):1755–1761. doi: 10.1038/bjc.2011.132

Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer

E E Vincent 1,5, D J E Elder 1,5, E C Thomas 1, L Phillips 2, C Morgan 1, J Pawade 3, M Sohail 3, M T May 4, M R Hetzel 2, J M Tavaré 1,*
PMCID: PMC3111153  PMID: 21505451

Abstract

Background:

The activity of the protein kinase Akt is frequently dysregulated in cancer and is an important factor in the growth and survival of tumour cells. Akt activation involves the phosphorylation of two residues: threonine 308 (Thr308) in the activation loop and serine 473 (Ser473) in the C-terminal hydrophobic motif. Phosphorylation of Ser473 has been extensively studied in tumour samples as a correlate for Akt activity, yet the phosphorylation of Thr308 or of downstream Akt substrates is rarely assessed.

Methods:

The phosphorylation status of Thr308 and Ser473 was compared with that of three separate Akt substrates – PRAS40, TSC2 and TBC1D4 – in fresh frozen samples of early-stage human non-small cell lung cancer (NSCLC).

Results:

Akt Thr308 phosphorylation correlated with the phosphorylation of each Akt substrate tested, whereas Akt Ser473 phosphorylation did not correlate with the phosphorylation of any of the substrates examined.

Conclusion:

The phosphorylation of Thr308 is a more reliable biomarker for the protein kinase activity of Akt in tumour samples than Ser473. Any evaluation of the link between Akt phosphorylation or activity in tumour samples and the prediction or prognosis of disease should, therefore, focus on measuring the phosphorylation of Akt on Thr308 and/or at least one downstream Akt substrate, rather than Akt Ser473 phosphorylation alone.

Keywords: protein kinase B, Akt, biomarker, tumour, phosphorylation

The stimulation of cell growth and survival by numerous growth factors involves the activation of the phosphoinositide 3-kinase (PI3-kinase). This leads to the production of phosphoinositide(3,4,5)trisphosphate (PI(3,4,5)P3) and the consequent activation of the protein serine/threonine kinase Akt (also known as protein kinase B). The activation of Akt involves the phosphorylation of two residues: threonine 308 (Thr308) in the activation loop of the kinase by the protein kinase PDK1, and serine 473 (Ser473) in the hydrophobic motif by the mTORC2 complex (Alessi et al, 1997; Vanhaesebroeck and Alessi, 2000; Sarbassov et al, 2005). Activated Akt then phosphorylates numerous downstream substrates, including glycogen synthase kinase-3 (GSK3α/β), tuberous sclerosis complex-2 (TSC2), Foxo-family transcription factors, Bad, Par-4, PRAS40 and TBC1D4 (Manning and Cantley, 2007). It is these proteins that together provide potent growth, survival and metabolic signals to the cell (Hanada et al, 2004; Goswami et al, 2005).

The Akt pathway represents one of the most frequently dysregulated pathways found in human cancer (Altomare and Testa, 2005; Cheng et al, 2005) and is a critical mediator of the survival and proliferative effects of several oncogenes including mutant forms of the EGF receptor, Ras and PI3-kinase, as well as the Bcr-Abl fusion protein (Yuan and Cantley, 2008). The activity of the Akt pathway is counteracted by the PI(3,4,5)P3 phosphatase, PTEN, and mutations in or haploinsufficiency of PTEN are frequently observed in human tumours (Li et al, 1998; Cantley and Neel, 1999; Ramaswamy et al, 1999; Sun et al, 1999).

Because of the importance of the Akt pathway in tumourigenesis, Akt activity represents a potential biomarker for use in disease prognosis or in predicting tumour response to therapeutics. This biomarker may provide an indicator of sensitivity or resistance to small molecule therapeutics directed at upstream regulators such as the epidermal growth factor receptor (EGFR) or PI3-kinase, as well as Akt itself (Pal et al, 2010).

This leads to the question of how best to evaluate Akt activity as a biomarker. In the vast majority of studies on Akt in cancer, the measurement of phosphorylation on Ser473 has been used as an indicator of Akt activity. However, using Ser473 as a measure of Akt activity often leads to contradictory conclusions regarding whether Akt activity is prognostic for various cancers. For example, in non-small cell lung cancer (NSCLC) phosphorylation of Akt on Ser473 has in some studies been found to correlate with poor prognosis (David et al, 2004; Tang et al, 2006; Lim et al, 2007), whereas others have found that it has no prognostic significance (Mukohara et al, 2003; Tsao et al, 2003; Massion et al, 2004). Contradictory observations have also been found in other types of tumour; phosphorylation on Ser473 has been correlated with poor prognosis in breast and ovarian cancer (Perez-Tenorio and Stal, 2002; Dai et al, 2005) whereas other studies find this not to be the case (Slipicevic et al, 2005; Al-Bazz et al, 2009). Interpretation of such data is confounded by whether Akt phosphorylation on Ser473 is a reliable surrogate for Akt activity, which is ultimately what is important for the proliferation and survival of the tumour cells.

A more reliable in vivo biomarker of Akt activity may be the phosphorylation of Thr308, arguably the more important regulator of Akt activity (Vanhaesebroeck and Alessi, 2000). Although much more rarely investigated than Ser473 phosphorylation, there are reports that the phosphorylation of Thr308 correlates with poor survival in NSCLC (Tsurutani et al, 2006) and acute myeloid leukaemia (Gallay et al, 2009) and, interestingly, in both reports no such correlation was seen with Akt Ser473 phosphorylation. This suggests that the extent of Thr308 phosphorylation may be the better predictor of Akt activity.

However, the most reliable measure of Akt activity in vivo may be through the analysis of the phosphorylation of downstream targets of the kinase along with the phosphorylation of Akt itself. There are very few studies that have done this.

We wished to carry out such an analysis for NSCLC as it continues to be a leading cause of cancer death worldwide. In addition, studies relating Akt activity to clinical outcome in NSCLC are contradictory possibly because they rely almost solely on the phosphorylation of Ser473 as a marker. We have therefore undertaken a detailed and quantitative examination of the activation of Akt in normal and patient-matched tumour tissue from individuals with NSCLC. Herein we analyse the phosphorylation of Akt on Ser473 and Thr308 and correlate this with the activity of the kinase as determined by the phosphorylation of three well-characterised substrates: PRAS40 (Nascimento and Ouwens, 2009), TSC2 (Cai et al, 2006) and TBC1D4 (Kane et al, 2002).

Materials and methods

Materials

Rabbit polyclonal pAkt (Thr308), pAkt (Ser473), pTBC1D4 (Thr642), pPRAS40 (Thr246) and pTSC (Ser939) antibodies were purchased from Cell Signalling Technology (Boston, MA, USA). Mouse anti-F1-ATPase antibody was from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Donkey horseradish peroxidase-conjugated anti-mouse IgG and anti-rabbit IgG antibodies were purchased from Jackson ImmunoResearch Laboratories (Bar Harbor, ME, USA).

Patients and tissue samples

Patients with suspected lung cancer were identified from an elective thoracic surgery list at the Bristol Royal Infirmary, Bristol, UK. A Research Nurse contacted study subjects regarding participation and informed consent was given to use their tumour and matched normal lung tissue. The study was approved by the local research ethics committee (REC no: 07/Q2002/6, South West 4 REC).

The research nurse was present at thoracic surgery to collect the tissue, which was surplus to diagnostic requirements. This was separated into individual samples of tumour and normal tissues, which were immediately snap frozen in liquid nitrogen. A pathologist recorded the histology and stage of the tumour, and made an assessment of the percentage of tumour cells present in each tumour sample. Only those NSCLC tumour samples comprising at least 90% of tumour cells were included further in the study. All samples were stored at −80 °C until required for analysis.

The cohort had an average age of 64.5 years, 71% were male, 10% were non-smokers, 10% had accumulated 1–10 pack years, 27% 11–30 pack years and 53% >30 pack years (one pack year being defined as 20 manufactured cigarettes smoked per day for 1 year). Three patients had previously been exposed to asbestos. Following surgery, all tumours were confirmed to be stage I/IIa and histology showed that 53% were adenocarcinomas, 40% squamous cell carcinomas and 3% bronchiolalveloar carcinomas.

Preparation of tissue lysates

Frozen tissue samples were homogenised using a Polytron homogeniser in 3 ml ice-cold extraction buffer (50 mM Tris pH 7.5, 120 mM NaCl, 1% (v/v) Nonidet-P40, 40 mM β-glycerophosphate, 1 mM benzamidine, 1 mM EDTA, 50 mM NaF, 10 mM Na4P2O7, 10 μg ml–1 pepstatin, 10 μg ml–1 antipain, 10 μg ml–1 leupeptin, 5 mM Na3VO4 and 2 mM phenylmethylsulphonyl fluoride). Samples were pulsed for 10 s followed by a 30-s incubation on ice; a procedure repeated three times. Tissue lysates were rotated end-over-end at 4 °C for 30 min, and rested on ice for 15 min before centrifugation at 16 000 g for 15 min to remove insoluble material. Protein concentration was determined by BCA assay (Thermo Scientific, Rockford, IL, USA). Tissue lysates were stored at −80 °C.

Western blot analysis

Lysates (15 μg protein) were solubilised by boiling in 4 × Laemmli sample buffer and separated by SDS–PAGE using 4-12% gradient gels (Invitrogen Ltd, Paisley, UK). Proteins were transferred to polyvinylidene difluoride membranes (Millipore, Hertfordshire, UK). Membranes were blocked using 5% (w/v) bovine serum albumin in TBS-T (20 mM Tris pH 7.4, 137 mM NaCl, 0.1% (v/v) Tween-20) for 1 h, washed five times in TBS-T and then incubated with primary antibody (1 μg ml–1) for 1 h in TBS-T containing 5% w/v bovine serum albumin. The membranes were again washed five times in TBS-T and then incubated with the appropriate secondary antibodies diluted in TBS-T for 1 h. Immunoblots were visualised using the enhanced chemiluminescence (ECL) detection system (Amersham Biosciences, Amersham, UK).

Data and statistical analysis

Three separate samples of tumour tissue and three separate samples of normal tissue from an individual patient were subjected to western blotting and ECL detection. Normal and tumour protein samples from individual patients were separated on different gels and therefore the absolute levels of phosphorylation between patients were not compared. The extent of phosphorylation of each protein was quantified by densitometric scanning of the western blot (Quantity One Software, Bio-Rad, Hemel Hempstead, UK). Data are expressed as mean±s.e.m., and the strength of evidence for the difference in phosphorylation between the normal and tumour samples was determined by Kruskal–Wallis rank order test (P<0.05). Changes in phosphorylation in tumour samples relative to normal samples were coded with the values 0 (signifying an increase observed at P⩽0.05), 1 (decrease at P⩽0.05) or 2 (no change, i.e., P>0.05) in the tumour tissue relative to normal. The Spearman's distribution-free rank correlation test was applied to the data to test pair-wise correlations between the phosphorylation of Akt on Thr308 or Ser473 and the phosphorylation of the three Akt substrates PRAS40, TSC2 and TBC1D4. Quantitatively similar results were obtained when analysing the data using the Pearson's correlation coefficient test (data not shown).

Results

The study cohort comprised 29 patients undergoing thoracic surgery for suspected lung cancer. Following resection from the patient, three samples of tumour were snap frozen in liquid nitrogen. Samples were confirmed by analysis of frozen sections to consist of at least 90% tumour tissue. Three samples of normal lung tissue were also taken from the resection margin surrounding the tumour and snap frozen. The use of patient-matched normal tissue allowed us to determine whether protein phosphorylation was increased, decreased or unchanged in the tumour relative to normal lung from that particular individual.

Analysis of Akt phosphorylation on Thr308 and Ser473

Three separate samples of tumour and three samples of patient-matched normal tissue were lysed and subjected to SDS–PAGE followed by western blotting for the level of phosphorylation of Akt on Thr308 and Ser473, as well as the phosphorylation of the well-characterised downstream Akt substrates PRAS40 (on Thr246), TSC2 (on Ser939) and TBC1D4 (on Thr642).

Figure 1A shows data compiled for the phosphorylation of Akt on Thr308 in all 29 tumour samples (dark grey bars) compared with samples of patient-matched normal tissue (light grey bars). In order to compare the data between patients, the data are reorganised in Figure 1B according to the magnitude of the fold change: from highest fold increase to highest fold decrease in tumour compared with normal tissue. Figure 2A and B shows a parallel analysis of the phosphorylation of Akt on Ser473.

Figure 1.

Figure 1

Open in a new tab

Phosphorylation of Akt on Thr308 in NSCLC tumour tissue in comparison with patient-matched normal lung tissue. Triplicate samples of lysate from patient-matched normal (N1–3) and tumour (T1–3) tissues were separated on SDS–PAGE gels. Phosphorylation of Akt on Thr308 was determined by western blotting with a pAkt-Thr308 antibody followed by quantitation by densitometric scanning. (A) Quantified data for all 29 patients. Each bar represents the average phosphorylation for normal (N1–3; light grey) or tumour (T1–3; black) tissue for each patient (mean±s.e.m.). The strength of evidence for a difference in phosphorylation between the normal and tumour samples was determined by Kruskal–Wallis test; *P<0.05. (B) The percentage change in Akt-Thr308 phosphorylation in tumour samples in comparison with patient-matched normal tissue where patients are ranked in order of the extent of the percentage change in phosphorylation.

Figure 2.

Figure 2

Open in a new tab

Phosphorylation of Akt on Ser473 in NSCLC tumour tissue in comparison with patient-matched normal lung tissue. Samples were western blotted and the data quantified exactly as described in Figure 1. (A) The extent of Ser473 phosphorylation in normal (N1–3; light grey) or tumour (T1–3; black) tissue for each patient (mean±s.e.m.; *P<0.05). (B) The percentage changes in Akt Ser473 phosphorylation in tumour samples in comparison with patient-matched normal tissue with patients are ranked according to the percentage change in phosphorylation.

Akt phosphorylation on Thr308 was increased in 12 out of 29 (41%) of tumours (at P<0.05; Kruskal–Wallis test) when compared with normal tissue. The magnitude of the change varied, but in four tumours this was in excess of a ten-fold increase. Akt Thr308 phosphorylation was decreased in 8 out of 29 (28%) of tumours (P<0.05); again the magnitude varied but in three tumours this was greater than a ten-fold decrease. In the remaining nine tumours, Akt Thr308 phosphorylation was apparently unchanged (i.e., P>0.05).

A similar analysis of the data for Akt phosphorylation on Ser473 showed that it was increased in 6 out of 29 tumours (21% P<0.05), decreased in 14 out of 29 tumours (48% P<0.05) and unchanged in the remaining 9 tumours, when compared with normal tissue.

The frequency of the increased phosphorylation was, therefore, less for Ser473 phosphorylation than we observed for Thr308, but conversely the decreases were more frequent. The reasons for the decreases observed are not known but may be the result of downregulation of Akt signalling in some tumours.

We next coded the data for Thr308 and Ser473 phosphorylation according to whether they increased (black) or decreased (grey) at P<0.05. The coded data are represented within the chart in Figure 3 and are grouped according to the direction of change in Thr308 phosphorylation. Of the 12 cases where Thr308 phosphorylation was increased relative to normal tissue (termed group Ia tumours in Figure 3), Ser473 phosphorylation was increased in parallel in only 6 cases. In three tumours (designated group Ib), Ser473 phosphorylation was regulated in a diametrically opposite manner to Thr308 phosphorylation.

Figure 3.

Figure 3

Open in a new tab

Examination of the correlation between Akt Thr308 and Ser473 phosphorylation and the phosphorylation of Akt substrates. Triplicate samples of normal and patient-matched tumour tissues were separated on SDS–PAGE gels. Phosphorylation of Akt (on Thr308 and Ser473) and three downstream substrate proteins (PRAS40-Thr246, TSC2-Ser939 and TBC1D4-Thr642) was determined by western blotting with phospho-specific antibodies. The data were quantified by densitometry and the strength of evidence of difference in phosphorylation between the normal and tumour samples was determined by Kruskal–Wallis test. Phosphorylation of each protein/site was then coded according to whether it increased (black), decreased (grey) at P⩽0.05 or remained unchanged (white; P>0.05) in the tumour samples relative to normal tissue. The coded data were then grouped according to the direction of change in Thr308 phosphorylation: patients in group I showed an increase, group 2 a decrease and group 3 no change. Group I were further subdivided according to the change in Akt Ser473 phosphorylation (group Ia showing an increase or no change, and group Ib a decrease).

In seven of the eight cases where Thr308 phosphorylation was decreased, Ser473 phosphorylation was decreased in parallel and these are termed group II tumours. In the nine cases where Thr308 phosphorylation was unchanged (P>0.05), Ser473 phosphorylation was also unchanged in five but was decreased in the remaining four cases (group III tumours).

To summarise, Akt Thr308 and Ser473 phosphorylation were regulated in an identical manner (increased, decreased or unchanged) in just 18 out of the 29 cases studied. Given the complex interplay between these sites with respect to regulation of kinase activity, this raised the question of which of Akt Thr308 or Ser473 phosphorylation correlates best with Akt activity.

Evaluation of the phosphorylation of Akt substrates

When active, Akt phosphorylates numerous downstream substrates that bring about the pleiotropic biological effects of this kinase. We undertook a detailed examination of the phosphorylation of three well-characterised Akt substrates in the tumour samples: PRAS40 (on Thr246), TSC2 (on Ser939) and TBC1D4 (on Thr642). PRAS40 and TSC2 are both important regulatory components of the mTOR complex. TBC1D4 is a Rab GTPase-activating protein that plays a role in the regulation of glucose metabolism.

The data for the phosphorylation of all three substrates are provided in Supplementary Figures 1–3, and are summarised in the chart of Figure 3. Examples of some of the originating western blot data are provided in Figure 4.

Figure 4.

Figure 4

Open in a new tab

Examples of Akt Thr308 and Ser473 phosphorylation, together with the phosphorylation of downstream substrates. Triplicate lysates of normal (N1–3) and patient-matched tumour (T1–3) tissues were separated on SDS–PAGE gels. Phosphorylation of Akt on Thr308 and Ser473, and of three downstream substrates, was determined by western blotting with phospho-specific antibodies as indicated. An anti-F1-ATPase antibody was used as a control for protein loading. (A) Examples (patients 11 and 24) of tumours in group Ia. (B) Examples of tumours from two patients (patients 17 and 27) in group Ib. (C) Examples of two patients (patients 4 and 7) in group II.

In the nine group Ia tumours, where Akt Thr308 phosphorylation was increased, the phosphorylation of at least one of the three Akt substrates was also increased (Figures 3 and 4A) in all except one patient (patient 18, Figure 3). In all three group Ib tumours, where Akt Thr308 phosphorylation was increased but Ser473 was decreased, the phosphorylation of all three Akt substrates was increased (Figures 3 and 4B), strongly suggesting that Thr308 phosphorylation correlates best with the activity of Akt towards downstream substrates.

In group II tumours, reduced Akt phosphorylation on Thr308 was accompanied by reduced phosphorylation of at least one of the three Akt substrates in all except two tumours (patients 14 and 16; Figures 3 and 4C). Finally, in the nine group III tumours, where Akt Thr308 phosphorylation was unchanged, the phosphorylation of all three Akt substrates was also unchanged in six out of nine patients (Figure 3).

The data in Figure 3 were examined using the Spearman's rank correlation test for pair-wise correlation between the phosphorylation of Akt on Thr308 or Ser473 and the phosphorylation of each of the substrates. The analysis is summarised in Table 1. This demonstrated that the phosphorylation of each of the three Akt substrates correlated with Akt phosphorylation on the activation loop Thr308 (P<0.01 in all three cases) but did not correlate with phosphorylation of Ser473 in the hydrophobic motif (P⩾0.05 in each case).

Table 1. Correlation between the phosphorylation of Akt on Thr308 or Ser473 and the phosphorylation of downstream Akt substrates.

  pPRAS40 pTSC2 pTBC1D4
Akt-pThr308
 R 0.752 0.676 0.465
 p <0.1 × 10–3 <0.1 × 10–3 8.3 × 10–3
       
Akt-pSer473
 R 0.352 0.229 0.137
 p 0.052 0.216 0.462
Open in a new tab

Abbreviations: Ser473=serine 473; Thr308=threonine 308.

The table provides the correlation coefficient (R) and degree of significance (p) obtained for each variable shown using the Spearman's pair-wise correlation test.

In some tumours, phosphorylation of a substrate was observed to increase under conditions where the phosphorylation of Akt and one or both of PRAS40 and TSC2 were unchanged or decreased. This was most specifically the case for TBC1D4 phosphorylation on Thr642 (hence the lower correlation with Akt Thr308 phosphorylation compared with PRAS40 and TSC2). TBC1D4 Thr642 has also been reported to be a substrate for p90 ribosomal S6 kinase 1 and serum- and glucocorticoid-induced protein kinase 1 (Geraghty et al, 2007), the activity of which may be elevated in these tumours. This possibility will require future investigation.

Discussion

In the era of targeted therapy, the assessment of Akt activity in tumours will move from determining its importance in the genesis of cancer to establishing its activity in individual tumours as a means of defining targeted treatment. It is critical that there are methods by which Akt activity can be reliably determined, in the particular tissue and pathological condition being examined or treated.

Lung cancer is the leading cause of cancer death worldwide and NSCLC accounts for 80% of all cases. In NSCLC, Akt activity represents an attractive and quantifiable biomarker for predictive, prognostic and pharmacodynamic purposes (Solomon and Pearson, 2009). The majority of studies aimed at evaluating the predictive power of Akt phosphorylation for patient survival have focussed on Ser473 rather than Thr308 phosphorylation, probably in large part because phosphoSer473 antibodies are relatively effective, particularly in immunohistochemical (IHC) analyses. As a consequence, few studies have analysed Akt phosphorylation on Thr308.

Our data strongly suggest that Akt phosphorylation on Thr308 is a much better indicator of the protein kinase activity of Akt in NSCLC than phosphorylation on Ser473 (Figure 3 and Table 1). We reached this conclusion through examining the correlation between Akt phosphorylation on each of Thr308 and Ser473, and the activity of the Akt kinase as indicated by the state of phosphorylation of three well-characterised Akt substrates: PRAS40, TSC2 and TBC1D4. The observation that Akt Thr308 phosphorylation is the better indicator of activity was most obvious in group Ib tumours in which the phosphorylation of Akt on Thr308 and all three Akt substrates were increased, but the phosphorylation of Akt on Ser473 was decreased (Figures 3 and 4B). However, across all tumours there was a significant correlation between Thr308 phosphorylation and the phosphorylation of all three substrates, but no such correlation for Ser473 phosphorylation.

Our conclusion is consistent with the fact that Thr308 is the major regulator of Akt kinase activity. For example, phosphorylation of purified Akt on Thr308 by recombinant active PDK1 increases Akt protein kinase activity by 30-fold (1, 28, 29), presumably as a result of a major conformational change in the enzyme that allows substrate binding and phosphorylation (Pearce et al, 2010). Independent phosphorylation of purified Akt on Ser473 in vitro by DNA-dependent protein kinase (DNA-PK) also activates Akt but only by approximately ten-fold (Feng et al, 2004). Studies with Akt phosphorylation site mutants suggest that the phosphorylation of Thr308 and Ser473 may act in synergy to stimulate Akt activity (Alessi et al, 1996). However, staurosporine attenuates the activation of Akt in cultured HEK293 cells stimulated with insulin in parallel with an inhibition of Thr308 phosphorylation, but has no effect on Ser473 phosphorylation (Hill et al, 2001). This observation is consistent with the fact that staurosporine potently inhibits PDK1 (32) but has little effect on mTORC2 (Hresko and Mueckler, 2005), which is widely agreed to be the physiologically relevant Ser473 kinase in most cell types (Sarbassov et al, 2005). Taken together, the data suggest that Ser473 does not play a significant role in regulating Akt activity in HEK293 cells and our results strongly suggest that Thr308 phosphorylation is the primary regulator of Akt activity, at least in NSCLC tumours.

That we demonstrate Thr308 phosphorylation to be a better marker for Akt activity than Ser473 phosphorylation could help to explain why Tsurutani et al (2006) found that Thr308 phosphorylation was a better predictor than Ser473 phosphorylation for poor overall survival in NSCLC. We propose that this was because these tumours possess the highest Akt activity, which was responsible for driving tumour cell proliferation and survival. As Ser473 is phosphorylated by the mTORC2 complex (and possibly integrin-linked kinase and DNA-PK in some cell types), measurements of its phosphorylation may report the activity of the upstream Ser473 kinase(s) rather than activity of Akt itself, and hence care should be exercised when using this phosphorylation site as a biomarker.

To our knowledge, no studies have assessed Akt activity in NSCLC by looking at phosphorylation of both Ser473 and Thr308 in addition to substrate phosphorylation. Although when studying Akt activation in NSCLC, Balsara et al (2004) found that the phosphorylation of two Akt substrates (mTOR and FKHR) was significantly associated with the phosphorylation of Akt on Ser473. There are notable differences in methodology between this study and ours that may explain the discrepancy in results with respect to the correlation of Ser473 with substrate phosphorylation. By rapidly flash freezing tissue samples, the current study was designed to minimise changes in phosphorylation whereas Balsara et al (2004) used archival paraffin-embedded samples that may not have been subject to such handling. Secondly, we obtained our data by a comparison of phosphorylation in tumour tissue with that in patient-matched normal tissue rather than correlating Akt and substrate phosphorylation in individual tumour sections.

A recent study reported that the phosphorylation of PRAS40 on Thr246 positively correlated with the activation of the PI3-kinase pathway and predicted an increased sensitivity of tumour cell growth to an Akt inhibitor in lung and breast cancer cell lines (Andersen et al, 2010). Taken together with our own data, showing PRAS40 to strongly correlate with Akt Thr308 phosphorylation, suggests that Akt Thr308 and/or PRAS40 Thr246 phosphorylation would be good candidate biomarkers to assess Akt activity in NSCLC.

The data in our current study suggest that the regulation of Akt activity in NSCLC is complex. Akt activity, as judged by increased phosphorylation of Akt on Thr308 and at least one downstream substrate, was elevated in 12 (41%) of the tumours we examined. We did not examine the upstream defects responsible for the activation of Akt; however, we did find that EGFR tyrosine phosphorylation was significantly elevated in 6 of these 12 tumours, suggesting that changes in EGFR activity might have been responsible (data not shown). Clearly, however, other mechanisms will also play a role such as increased activity of the insulin-like growth factor receptor or cMet and PTEN mutation status.

It is of interest that Akt Thr308 phosphorylation and activity were reduced in a significant number of tumours (group II; Figure 3). This may be a result of feedback inhibition of Akt because of persistent activation of the downstream mTOR complex, as previously reported (Shah et al, 2004; O’Reilly et al, 2006). Therefore, we propose that this group of tumours would be unlikely to respond to inhibitors of Akt and PI3-kinase.

Our observations have important consequences for the future use of Akt as a molecular biomarker in predicting the efficacy of targeted therapy against the PI3-kinase/Akt pathway and its regulators. We propose that any evaluation of the link between Akt phosphorylation in tumour samples and the prediction or prognosis of disease should focus on the phosphorylation of Thr308 and/or at least one downstream Akt substrate, rather than Ser473 phosphorylation alone, in order to more reliably determine the activity of the kinase and thus better guide disease prognosis and treatment. Furthermore, although our current results pertain to NSCLC, they almost certainly have relevance to other tumour types in which this kinase plays a role in tumourigenesis.

Acknowledgments

We are grateful to the Wellcome Trust and Bristol Friends of Oncology for their financial support of this work. We thank Mr JA Morgan for his assistance with tissue collection during surgery, Jenny Crick and Victoria Jennings for technical assistance and Chris Paraskeva and Ann Williams for useful discussions. This manuscript is dedicated to the memory of Mr Morgan.

Footnotes

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

The authors declare no conflict of interest.

Supplementary Material

Supplementary Figure 1
Click here for additional data file. (463.3KB, pdf)
Supplementary Figure 2
Click here for additional data file. (459.1KB, pdf)
Supplementary Figure 3
Click here for additional data file. (469.3KB, pdf)
Supplementary Figure Legends
Click here for additional data file. (22.5KB, doc)

References

  1. Al-Bazz YO, Brown BL, Underwood JC, Stewart RL, Dobson PR (2009) Immuno-analysis of phospho-Akt in primary human breast cancers. Int J Oncol 35: 1159–1167 [DOI] [PubMed] [Google Scholar]
  2. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings BA (1996) Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541–6551 [PMC free article] [PubMed] [Google Scholar]
  3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PRJ, Reese CB, Cohen P (1997) Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 7: 261–269 [DOI] [PubMed] [Google Scholar]
  4. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455–7464 [DOI] [PubMed] [Google Scholar]
  5. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP (2010) Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2: 43–55 [DOI] [PubMed] [Google Scholar]
  6. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053–2059 [DOI] [PubMed] [Google Scholar]
  7. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, Shen J, Guo R, Johnson CL, Kiguchi K, Walker CL (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173: 279–289 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cantley LC, Neel BG (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240–4245 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482–7492 [DOI] [PubMed] [Google Scholar]
  10. Dai DL, Martinka M, Li G (2005) Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol 23: 1473–1482 [DOI] [PubMed] [Google Scholar]
  11. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M, Brody AR (2004) Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865–6871 [DOI] [PubMed] [Google Scholar]
  12. Feng J, Park J, Cron P, Hess D, Hemmings BA (2004) Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 279: 41189–41196 [DOI] [PubMed] [Google Scholar]
  13. Gallay N, Dos Santos C, Cuzin L, Bousquet M, Simmonet Gouy V, Chaussade C, Attal M, Payrastre B, Demur C, Recher C (2009) The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia 23: 1029–1038 [DOI] [PubMed] [Google Scholar]
  14. Geraghty KM, Chen S, Harthill JE, Ibrahim AF, Toth R, Morrice NA, Vandermoere F, Moorhead GB, Hardie DG, MacKintosh C (2007) Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR. Biochem J 407: 231–241 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goswami A, Burikhanov R, de Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T, Rangnekar VM (2005) Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 20: 33–44 [DOI] [PubMed] [Google Scholar]
  16. Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta 1697: 3–16 [DOI] [PubMed] [Google Scholar]
  17. Hill MM, Andjelkovic M, Brazil DP, Ferrari S, Fabbro D, Hemmings BA (2001) Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase. J Biol Chem 276: 25643–25646 [DOI] [PubMed] [Google Scholar]
  18. Hresko RC, Mueckler M (2005) mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 280: 40406–40416 [DOI] [PubMed] [Google Scholar]
  19. Kane S, Sano H, Liu SC, Asara JM, Lane WS, Garner CC, Lienhard GE (2002) A method to identify serine kinase substrates. Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J Biol Chem 277: 22115–22118 [DOI] [PubMed] [Google Scholar]
  20. Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N, Parsons R (1998) The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 58: 5667–5672 [PubMed] [Google Scholar]
  21. Lim WT, Zhang WH, Miller CR, Watters JW, Gao F, Viswanathan A, Govindan R, McLeod HL (2007) PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer. Oncol Rep 17: 853–857 [PubMed] [Google Scholar]
  22. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261–1274 [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Massion PP, Taflan PM, Shyr Y, Rahman SM, Yildiz P, Shakthour B, Edgerton ME, Ninan M, Andersen JJ, Gonzalez AL (2004) Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170: 1088–1094 [DOI] [PubMed] [Google Scholar]
  24. Mukohara T, Kudoh S, Yamauchi S, Kimura T, Yoshimura N, Kanazawa H, Hirata K, Wanibuchi H, Fukushima S, Inoue K, Yoshikawa J (2003) Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41: 123–130 [DOI] [PubMed] [Google Scholar]
  25. Nascimento EB, Ouwens DM (2009) PRAS40: target or modulator of mTORC1 signalling and insulin action? Arch Physiol Biochem 115: 163–175 [DOI] [PubMed] [Google Scholar]
  26. O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508 [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Pal SK, Reckamp K, Yu H, Figlin RA (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355–1366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pearce LR, Komander D, Alessi DR (2010) The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11: 9–22 [DOI] [PubMed] [Google Scholar]
  29. Perez-Tenorio G, Stal O (2002) Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 86: 540–545 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, Sellers WR (1999) Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA 96: 2110–2115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101 [DOI] [PubMed] [Google Scholar]
  32. Shah OJ, Wang Z, Hunter T (2004) Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr Biol 14: 1650–1656 [DOI] [PubMed] [Google Scholar]
  33. Slipicevic A, Holm R, Nguyen MT, Bohler PJ, Davidson B, Florenes VA (2005) Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol 124: 528–536 [DOI] [PubMed] [Google Scholar]
  34. Solomon B, Pearson RB (2009) Class IA phosphatidylinositol 3-kinase signaling in non-small cell lung cancer. J Thorac Oncol 4: 787–791 [DOI] [PubMed] [Google Scholar]
  35. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, Wu H (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci USA 96: 6199–6204 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Tang JM, He QY, Guo RX, Chang XJ (2006) Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181–191 [DOI] [PubMed] [Google Scholar]
  37. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM (2003) Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12: 660–664 [PubMed] [Google Scholar]
  38. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J, Dennis PA (2006) Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. J Clin Oncol 24: 306–314 [DOI] [PubMed] [Google Scholar]
  39. Vanhaesebroeck B, Alessi DR (2000) The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346: 561–576 [PMC free article] [PubMed] [Google Scholar]
  40. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497–5510 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figure 1
Click here for additional data file. (463.3KB, pdf)
Supplementary Figure 2
Click here for additional data file. (459.1KB, pdf)
Supplementary Figure 3
Click here for additional data file. (469.3KB, pdf)
Supplementary Figure Legends
Click here for additional data file. (22.5KB, doc)

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES